Gilead Sciences licensed two helicase‑primase inhibitors for recurrent genital herpes—ABI‑1179 and ABI‑5366—from Assembly Biosciences for $35 million upfront. Both candidates are in Phase 1b and demonstrated antiviral activity and lesion reduction in early trials, with profiles supportive of once‑weekly oral dosing. The transaction completes an option exercise tied to Gilead’s earlier pipeline deal with Assembly and preserves milestone and royalty upside for Assembly. Gilead’s move illustrates continued large‑cap interest in oral antivirals for chronic viral diseases.